Avadel Pharmaceuticals (AVDL) Non-Current Receivables (2016 - 2022)
Historic Non-Current Receivables for Avadel Pharmaceuticals (AVDL) over the last 11 years, with Q3 2022 value amounting to $1.1 million.
- Avadel Pharmaceuticals' Non-Current Receivables rose 1831.43% to $1.1 million in Q3 2022 from the same period last year, while for Sep 2022 it was $1.1 million, marking a year-over-year increase of 1831.43%. This contributed to the annual value of $1.2 million for FY2021, which is 6444.12% down from last year.
- As of Q3 2022, Avadel Pharmaceuticals' Non-Current Receivables stood at $1.1 million, which was up 1831.43% from $1.2 million recorded in Q2 2022.
- In the past 5 years, Avadel Pharmaceuticals' Non-Current Receivables ranged from a high of $7.8 million in Q2 2019 and a low of $961000.0 during Q3 2021
- Its 5-year average for Non-Current Receivables is $4.5 million, with a median of $5.9 million in 2018.
- As far as peak fluctuations go, Avadel Pharmaceuticals' Non-Current Receivables surged by 14636.89% in 2018, and later crashed by 8465.74% in 2021.
- Avadel Pharmaceuticals' Non-Current Receivables (Quarter) stood at $7.3 million in 2018, then fell by 13.06% to $6.3 million in 2019, then plummeted by 45.51% to $3.4 million in 2020, then plummeted by 64.44% to $1.2 million in 2021, then decreased by 7.18% to $1.1 million in 2022.
- Its Non-Current Receivables stands at $1.1 million for Q3 2022, versus $1.2 million for Q2 2022 and $1.2 million for Q1 2022.